Trial
NCT03506373
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Mayo Clinic
Collaborators
—
Condition
Recurrent Waldenstrom Macroglobulinemia
Intervention
Ibrutinib
Why stopped
Discontinued after interim analysis for futility; no treatment successes observed in the first 12 patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-05